2019
Potential MMP2-mediated availability of HLA binding, mutant ECM peptides reflects better melanoma survival rates and greater T-cell infiltrates
Zaman S, Chobrutskiy BI, Patel JS, Callahan BM, Mihyu MM, Diviney A, Blanck G. Potential MMP2-mediated availability of HLA binding, mutant ECM peptides reflects better melanoma survival rates and greater T-cell infiltrates. Laboratory Investigation 2019, 99: 1287-1295. PMID: 31019293, DOI: 10.1038/s41374-019-0248-3.Peer-Reviewed Original ResearchConceptsMutant amino acidsAmino acidsStructural proteinsExtracellular matrix structural proteinsMatrix metalloproteinase-2Cancer progressionLate-stage cancer developmentMutant peptidesECM structural proteinsMatrix structural proteinsBioinformatics approachProtein mutantsProtease functionECM peptidesSuch proteasesMutantsPotential substratesCancer developmentProteaseMelanoma samplesProteinSpread of cancerTumor samplesMetalloproteinase-2Cancer microenvironment
2018
Mutant cytoskeletal and ECM peptides sensitive to the ST14 protease are associated with a worse outcome for glioblastoma multiforme
Zaman S, Chobrutskiy BI, Patel JS, Callahan BM, Tong WL, Blanck G. Mutant cytoskeletal and ECM peptides sensitive to the ST14 protease are associated with a worse outcome for glioblastoma multiforme. Biochemical And Biophysical Research Communications 2018, 503: 2218-2225. PMID: 29953855, DOI: 10.1016/j.bbrc.2018.06.141.Peer-Reviewed Original ResearchConceptsT cell receptorAa substitutionsExtracellular matrix-related proteinsMatrix-related proteinsAmino acid substitutionsTransmembrane serine proteaseBioinformatics approachECM peptidesProtease sensitivityAcid substitutionsSerine proteasesCancer developmentProteasePeptide sequencesBarcodesHigh binding affinityBinding affinitiesCancer datasetsClass IRecombinationExome filesCytoskeletalCytoskeletonSubstitutionGlioblastoma multiforme